Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.
This is the second precision oncology drug approved by the agency for patients with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer.
The partnership goes hand-in-hand with Genentech's new precision basket trial, for which it will identify and enroll patients across OneOncology's network.
The researchers said their findings could explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenic therapies alone.
The Norwegian company will receive $200 million upfront from Genentech for the rights to its investigational neoantigen-based cancer vaccine, VB10.NEO.
